2μg (R: reducing condition, N: non-reducing condition).
lL-7 R alpha&TSLP R Heterodimer, Fc Chimera&Fc Chimera Protein, Human
lL-7 R alpha&TSLP R Heterodimer, Fc Chimera&Fc Chimera Protein, Human
Price:
Regular price
$210 USD
Regular price
Sale price
$210 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Species | Human |
| Synonyms | IL7Ra, CD127, TSLP R, CRLF2, IL-XR, ILXR, p2RY8, CRLF2 fusion, TSLP receptor |
| Accession | P16871-1、Q9HC73-1 |
| Amino Acid Sequence | Glu 21-Asp 239 (lL-7 R alpha) with Human IgG1 Fc at the C-Terminus&Gln 23-Lys 231(TSLP R) with Human IgG1 Fc at the C-Terminus |
| Expression System | HEK293 |
| Molecular Weight | 60-100kDa (Reducing) |
| Endotoxin | <0.1EU/μg |
| Tag | Human IgG1 Fc |
| Physical Appearance | Lyophilized powder |
| Storage Buffer | PBS, 5% trehalose, pH7.4 |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
| Stability & Storage |
· 12 months from date of receipt,lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃under sterile conditions after reconstitution. · 1 week, 2 to 8℃under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles. |
| Reference |
1. Lipworth B J, Han J K, Desrosiers M, et al. Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps[J]. New England Journal of Medicine, 2025, 392: 1178-1188. 2. Ebina-Shibuya R, Leonard W J. Role of thymic stromal lymphopoietin in allergy and beyond[J]. Nature Reviews Immunology, 2023, 23(1): 24-37. 3. Liao C, Mennillo E, Kattah M G, et al. TSLP links intestinal nutrient sensing with amplification of the ILC2-tuft cell circuit[J]. Nature Immunology, 2025, 26(12): 2218-2226. |
Background
The heterodimer formed by interleukin-7 receptor α (IL-7Rα, CD127) and the thymic stromal lymphopoietin receptor (TSLPR, CRLF2) constitutes the functional receptor complex for TSLP. Both chains are type I cytokine receptors: TSLPR provides the principal ligand-binding interface, whereas IL-7Rα is the shared signaling subunit. TSLP first engages TSLPR to form a binary pre-complex, which then recruits IL-7Rα to assemble a ternary complex; this triggers JAK1/JAK2-mediated activation of STAT5, together with PI3K-AKT and MAPK signaling. The complex drives dendritic-cell maturation, Th2 polarization, ILC2 activation, and basophil/mast-cell responses, placing it at the core of the epithelial alarmin axis. Clinically, tezepelumab—which blocks TSLP binding to this heterodimeric receptor—is approved for severe asthma and chronic rhinosinusitis with nasal polyps; inhaled anti-TSLP antibody fragments and bispecific antibodies are in development. In addition, CRLF2 dysregulation, including P2RY8::CRLF2 rearrangements, is a driver and therapeutic target in Ph-like acute lymphoblastic leukemia, highlighting the broader translational importance of this receptor complex.
Picture
Picture
SDS-PAGE
SEC-HPLC
The purity of lL-7 R alpha&TSLP R Heterodimer, Fc Chimera&Fc Chimera Protein, Human is more than 95% determined by SEC-HPLC.
ELISA
Immobilized lL-7 R alpha&TSLP R Heterodimer, Fc Chimera&Fc Chimera Protein, Human (Cat. No.UA016180) at 5 μg/mL (100 μL/well) can bind Biotinylated TSLP His&Avi Tag Protein, Human (Cat. No.UA011305) with a linear range of 0.94-1.3 ng/ml.
